Skip to main content

Table 2 Shows the endpoints reported by each of the included trials

From: Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials

Trials No of patients (DAPT + TAPT) Follow up period (month) Reported endpoints/outcomes
Han 2009 [6] 263 12 MACEs, TVR, and ADR.
Lee 2011 [33] 176 12 MACEs, TVR, TLR, ST, D/MI/TVR, BL and ADR.
Lee 2008 [5] 400 9 MACEs, TVR, TLR, ST, D/MI/TVR, BL and ADR.
Lee 2007 [34] 166 9 MACEs, TVR, TLR, ST, D/MI/TVR, BL and ADR.
Yang 2011 [35] 154 PRU and PA
Yang 2007 [36] 55 7 PA
Capranzano 2012 [37] 80 1 PRU and PRI
Angiolillo 2008 [38] 40 1 PRI and PA
Angiolillo 2011 [39] 106 1 PRI
Ha 2013 [40] 84 2 PRU and PA
  1. Abbreviations: MACEs major adverse cardiac effects, TVR target vessel revascularization, TLR target lesion revascularization, BL bleeding, ST stent thrombosis, ADR adverse drug reactions, D death, MI myocardial infarction, PA platelet aggregation, PRI platelet reactivity index, PRU platelet reactivity unit